Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial

Sci Rep. 2024 Jun 3;14(1):12685. doi: 10.1038/s41598-024-63443-8.. (Sci)

Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial

Jäger R, Abou Sawan S, Purpura M, Grube B, Röske Y, De Costa P, Chong PW.

Abstract

Obesity is a global health concern associated with numerous chronic diseases.  Finding safe and effective weight management strategies is crucial. This study investigated the efficacy of a proprietary alpha-amylase inhibitor formulation derived from white kidney bean (Phaseolus vulgaris L.) in promoting weight loss and fat reduction. A 12-week, double-blind, placebo-controlled, randomized trial involving overweight or obese adults assessed the impact of the formulation compared to a placebo. Participants taking the white kidney bean extract showed statistically significant reductions in body weight, body mass index (BMI), waist circumference, and body fat percentage compared to those receiving the placebo.

These findings suggest that a proprietary alpha-amylase inhibitor formulation from white kidney bean may be a promising adjunct for weight management and reducing body fat.

Keywords: BMI, Body shaping, Fat mass, Obesity, Weight management.

Introduction

Obesity has become a major public health issue worldwide, increasing the risk of chronic diseases like type 2 diabetes, cardiovascular disease, and certain cancers. Effective weight management strategies are crucial for addressing this epidemic.  While lifestyle modifications like diet and exercise are essential, pharmacological interventions can provide additional support. This study focuses on alpha-amylase inhibitors, enzymes that block the breakdown of carbohydrates in the digestive system, potentially leading to reduced calorie absorption and subsequent weight loss.

This randomized controlled trial aimed to evaluate the efficacy and safety of a proprietary alpha-amylase inhibitor formulation derived from white kidney bean (Phaseolus vulgaris L.) for weight management in overweight or obese adults.

Methodology

This study employed a double-blind, placebo-controlled, randomized design. Participants were randomly assigned to receive either the white kidney bean extract or a placebo for 12 weeks. The primary outcome measures included changes in body weight, BMI, waist circumference, and body fat percentage. Secondary outcomes assessed safety and tolerability. Statistical analyses compared the treatment group with the placebo group.

Results

The results demonstrated that participants who received the white kidney bean extract experienced statistically significant reductions in body weight, BMI, waist circumference, and body fat percentage compared to those who received the placebo. The treatment was well-tolerated, with no serious adverse events reported.

Discussion and Conclusion

This study provides evidence that a proprietary alpha-amylase inhibitor formulation derived from white kidney bean can effectively promote weight loss and reduce body fat in overweight or obese adults. These findings support the potential of this natural extract as a safe and effective adjunct for weight management strategies. Further research is warranted to explore long-term efficacy and optimal dosing regimens.

Limitations Noted

The study had a relatively small sample size, limiting the generalizability of the findings. The duration of the intervention was 12 weeks, which may not be sufficient to assess long-term effects.

Acknowledgements

This study was sponsored by InQpharm Consumer Health Ltd (Abertillery, United Kingdom). and financially supported by Perrigo CSCI (Nazareth, Belgium), Pharmachem (Kearney, NJ, USA), and Fytexia SAS (Vendres, France). Phase 2 was supplied by Pharmachem (Kearney, NJ, USA). Investigation products (Phase 2) and placebo were manufactured by InQpharm.

Ethical Considerations:

The study protocol was approved by an independent ethics committee, and all participants provided informed consent before enrollment.

Source Citation

Jäger R et al.. (Sci). Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial. Sci Rep. 2024 Jun 3;14(1):12685. doi: 10.1038/s41598-024-63443-8.

Legal and Ethical Use Statement

This summary is created for educational and informational purposes only. It is not intended as medical advice. Always consult with qualified healthcare professionals for medical decisions. The original research article should be referenced for complete details and context.